...
首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms
【24h】

Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms

机译:法呢X受体激动剂obeticholic酸和赤铁氧胆酸在夹层培养的人肝细胞中增加胆汁酸流动:功能证据和机制

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The farnesoid X receptor (FXR) is a nuclear receptor that regulates genes involved in bile acid homeostasis. FXR agonists, obeticholic acid (OCA) and chenodeoxycholic acid (CDCA), increase mRNA expression of efflux transporters in sandwich-cultured human hepatocytes (SCHH). This study evaluated the effects of OCA and CDCA treatment on the uptake, basolateral efflux, and biliary excretion of a model bile acid, taurocholate (TCA), in SCHH. In addition, changes in the protein expression of TCA uptake and efflux transporters were investigated. SCHH were treated with 1 mu M OCA, 100 mu M CDCA, or vehicle control for 72 hours followed by quantification of deuterated TCA uptake and efflux over time in Ca2+-containing and Ca2+-free conditions (n = 3 donors). A mechanistic pharmacokinetic model was fit to the TCA mass-time data to obtain estimates for total uptake clearance (CLUptake), total intrinsic basolateral efflux clearance (CLint,BL), and total intrinsic biliary clearance (CLint,Bile). Modeling results revealed that FXR agonists significantly increased CLint,BL by 6-fold and significantly increased CLint,Bile by 2-fold, with minimal effect on CLUptake. Immunoblotting showed that protein levels of the basolateral transporter subunits organic solute transporter alpha and beta (OST alpha and OST beta) in FXR agonist-treated SCHH were significantly induced by 2.5-and 10-fold, respectively. FXR agonist-mediated changes in the expression of other TCA transporters in SCHH were modest. In conclusion, this is the first report demonstrating that OCA and CDCA increased TCA efflux in SCHH, which contributed to reduced intracellular TCA concentrations. Increased basolateral efflux of TCA was consistent with increased OST alpha/beta protein expression in OCA- and CDCA-treated SCHH.
机译:法呢曲线X受体(FXR)是一种核受体,调节参与胆汁酸痛的基因。 FXR激动剂,obeticholic acid acid acid acid acid(oca)和chenodeoxcholic acid(cdca),增加了夹心培养的人肝细胞(Schh)中流出转运蛋白的mRNA表达。该研究评估了OCA和CDCA治疗对乳房模型胆汁酸,Taurocholate(TCA)的摄取,基石外渗和胆道排泄的影响。此外,研究了TCA摄取和流出转运蛋白的蛋白质表达的变化。用1μmOCA,100μMCDCA或载体对照治疗SchH 72小时,然后在Ca2 + - 可携带和Ca2 + -FREE条件下定量氘代TCA摄取和流出随时间(n = 3供体)。机械药代理模型适用于TCA质量时间数据,以获得总摄取间隙(Cluctake),总内在基底外侧流出间隙(克林特,BL)和总内在胆汁间隙(克林特,胆汁)的估计。建模结果显示,FXR激动剂显着增加克林特,BL> 6倍,显着增加克林,胆汁含量为2倍,对裂扰有最小的影响。免疫印迹表明,基石转运蛋白有机溶质转运蛋白α和β(OSTα和OSTβ)的蛋白质水平分别显着诱导了FXR激动剂治疗的SchH中的> 2.5-10倍。 FXR激动剂介导的Schh中其他TCA转运蛋白表达的变化是适度的。总之,这是第一份报告,证明OCA和CDCA增加了SCHH的TCA流出,这有助于降低细胞内TCA浓度。 TCA的增加的基石外渗透均与OCA-和CDCA处理的SchH中的OSTα/β蛋白表达增加一致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号